REVO

meerecompany (CEO Joon Koo Kim) announced on the 19th that its Surgical Robot Division signed a Memorandum of Agreement (MOA) with Korea Cancer Center Hospital on June 17 to jointly operate a robotic surgery training program for Korean and international medical professionals.

The signing ceremony was attended by key figures, including Dong Ho Kim (Director of Korea Cancer Center Hospital), Dr.Kang Hyon Song (Director of the Robotic Surgery Center), Dr.Myung-Chul Lee (Department of Otolaryngology), and Ho Kun Lee (Executive Vice President and Head of the Surgical Robot Division at meerecompany).

Korea Cancer Center Hospital, a recognized training destination from countries such as Thailand, Vietnam, and Mongolia, has actively conducted surgical observation using the Revo-i. With the recent MOA, the hospital is now designated as an official training center for the Revo SurgeSync Camp (SSC), further solidifying its role as an international training hub.

meerecompany plans to continue expanding partnerships with leading hospitals in Korea and remain committed to cultivating skilled robotic surgeons. In particular, the SSC program will strengthen collaboration with both domestic and international medical professionals, while continuously developing customized, hands-on curricula that reflect real clinical needs.

Dong Ho Kim, Director of Korea Cancer Center Hospital, stated, "This MOA marks a meaningful starting point for sharing the hospital's accumulated expertise in robotic surgery with global professionals and promoting the spread of safe, standardized surgical techniques. Moving forward, we will continue to contribute to the development of medical technologies and the training, based on our extensive clinical experience and educational infrastructure.“

Ho Kun Lee, Executive Vice President and Head of meerecompany’s Surgical Robot Division, added, "While global competition in surgical robotics is intensifying, we expect great synergy through this collaboration. We will continue our efforts to help more surgeons around the world experience the excellence of Revo-i’s technology and clinical value firsthand."

Korean article: https://www.medigatenews.com/news/3271867975